What did @veslybea actually say?
At seven weeks on Wegovy 0.5mg, @veslybea reports losing 6 pounds, going from 167 to 161 lbs. She's 4'11" and 26 years old. She frames this as roughly "one pound per week," says she hasn't been eating well or exercising consistently, and credits her boyfriend for reframing the result: not losing much, but not gaining either. She expects bigger changes when she moves to 1mg.
To her credit, she doesn't oversell the drug. She openly admits to "binging candy" and eating chocolate, and says she knows she's not doing her part. That kind of honesty is genuinely rare in GLP-1 content on TikTok, where before-and-after transformations dominate and disclaimers are an afterthought.
She also references a government recommendation of "one to one and a half pounds a week" as a healthy loss rate, which is worth checking.
Does the science back this up?
The 1 to 1.5 lbs per week figure is roughly accurate as a general guideline, but it's more nuanced than that in the context of semaglutide. The STEP 1 trial showed significantly more weight loss over time, but that was at the 2.4mg maintenance dose, not 0.5mg.
At the 0.5mg titration dose, Wegovy is not at therapeutic levels. The drug is dosed this low specifically to minimize side effects like nausea and vomiting, not to drive weight loss. The prescribing information and the clinical trial data both make clear that the dose escalation schedule, which moves from 0.25mg to 0.5mg to 1mg and eventually to 2.4mg, is about tolerability, not efficacy. Wilding et al. (2021, NEJM) showed the 2.4mg dose produced an average 14.9% body weight reduction over 68 weeks. Six pounds in seven weeks at a starting weight of 167 lbs is about 3.6%, which is reasonable for someone still in titration who isn't following dietary guidance.
Her observation that "we see the most changes at one" is partially right directionally, but the biggest effects in trials emerged at the full 2.4mg dose.
What did they get wrong (or right)?
She got more right than wrong, which is not what I expected going in.
The "one to one and a half pounds per week" recommendation she cites does align with CDC guidance and general clinical weight management targets. It's a reasonable benchmark. Not wrong.
Her self-assessment is accurate. Without consistent exercise or dietary changes, GLP-1 medications produce suboptimal results. Davies et al. (2021, Lancet Diabetes and Endocrinology) found that lifestyle intervention combined with semaglutide significantly outperformed semaglutide alone. She knows this. She says it plainly.
Where she's slightly off: framing 1mg as the dose where "we see the most changes." In clinical trials, 1mg is still a sub-maintenance dose. The STEP program consistently found the greatest weight loss at 2.4mg. At 1mg, patients see more effect than at 0.5mg, yes, but calling it the peak is misleading.
Also worth noting: she mentions potential insurance issues when she starts her new job. That's a real and underreported problem with Wegovy access, and it matters clinically. Stopping and restarting GLP-1 therapy mid-course can affect outcomes.
What should you actually know?
If you're on Wegovy and feeling discouraged at the titration dose, this is the most important thing to understand: the 0.25mg and 0.5mg doses are not meant to produce dramatic weight loss. They exist to help your body adjust. Expecting the drug to carry you at these doses, especially without dietary changes, is setting yourself up for disappointment.
The STEP 1 trial (Wilding et al., 2021, NEJM) enrolled patients at 2.4mg maintenance dose with lifestyle counseling. That context matters. Real-world results at lower doses, without consistent behavioral support, will look different from the trial data. That doesn't mean the drug isn't working. It means you're still in the setup phase.
@veslybea's boyfriend actually made a clinically relevant point: maintaining weight without gaining during a period of poor dietary adherence is not nothing. GLP-1 medications can reduce food reward signaling even before significant weight loss occurs (Blundell et al., 2017, Diabetes, Obesity and Metabolism). Holding the line matters.
One thing nobody in these videos talks about: what happens when you stop. Weight regain after GLP-1 discontinuation is substantial. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained two-thirds of their lost weight within a year of stopping. The insurance issue she mentions at the end of the video is not a minor footnote. It's a clinical risk.
Bottom line
This is one of the more honest GLP-1 videos I've reviewed. She's not promising miracles. She's showing a real, imperfect experience at a dose that isn't designed to produce dramatic results yet. The science mostly backs what she's saying, with the caveat that her expectations for 1mg should be tempered. The biggest weight loss in trials happened at 2.4mg, not 1mg. And anyone watching this who's thinking about starting Wegovy needs to understand that the drug is not a substitute for behavioral change. It's a tool that works better when you use the other tools too.